The advent of immune checkpoint blockade (ICB) has transformed cancer therapeutics with the introduction of inhibitors of programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4). The gene discussed is CD274; the disease is cancer.